MORTIMER IAN
SEC CIK 1619961 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| XENE | Xenon Pharmaceuticals Inc. | Pres, CEO, INTERIM CFO, Dir | 19.9K | — | $24.82M | 15 | 2023-05-24 | 2026-03-13 |
Most active insiders at XENE, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | MORTIMER IAN | Pres, CEO, INTERIM CFO, Dir | — | $21.30M |
| 2 | KENNEY CHRISTOPHER JOHN | Chief Medical Off | — | $670.3K |
| 3 | GANNON STEVEN | Dir | — | $640.6K |
| 4 | DiFabio Andrea | CLO | — | $230.8K |
| 5 | PATOU GARY | Dir | — | $70.3K |
| 6 | Cannon Gillian | Dir | — | $63.2K |
| 7 | GAROFALO ELIZABETH A. | Dir | — | — |
| 8 | Gover Justin D. | Dir | — | — |
| 9 | Svoronos Dawn | Dir | — | — |
| 10 | Machado Patrick | Dir | — | — |
Transactions 15
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-03-13 | 2026-03-12 | XENE | Xenon Pharmaceuticals Inc. | MORTIMER IAN | Pres, CEO, Dir | M - OptEx | — | +12.5K | 27.2K | +85% | — |
| DT | 2026-03-13 | 2026-03-13 | XENE | Xenon Pharmaceuticals Inc. | MORTIMER IAN | Pres, CEO, Dir | S - Sale+OE | $55.23 | -7,308 | 19.9K | -27% | -$403.6K |
| DMT | 2026-03-11 | 2026-03-09 | XENE | Xenon Pharmaceuticals Inc. | MORTIMER IAN | Pres, CEO, Dir | M - OptEx | $6.74 | +290.0K | 26.0K | New | +$1.95M |
| DMT | 2026-03-11 | 2026-03-09+ | XENE | Xenon Pharmaceuticals Inc. | MORTIMER IAN | Pres, CEO, Dir | S - Sale+OE | $60.32 | -281.3K | 14.7K | -95% | -$16.97M |
| DMT | 2026-01-02 | 2026-01-02 | XENE | Xenon Pharmaceuticals Inc. | MORTIMER IAN | Pres, CEO, Dir | S - Sale+OE | $44.43 | -40.0K | 6,000 | -87% | -$1.78M |
| DT | 2026-01-02 | 2026-01-02 | XENE | Xenon Pharmaceuticals Inc. | MORTIMER IAN | Pres, CEO, Dir | M - OptEx | $7.49 | +40.0K | 46.0K | +667% | +$299.6K |
| MT | 2025-12-09 | 2025-12-05+ | XENE | Xenon Pharmaceuticals Inc. | MORTIMER IAN | Pres, CEO, Dir | S - Sale | $45.33 | -25.2K | 16.8K | -60% | -$1.14M |
| T | 2025-12-03 | 2025-11-28 | XENE | Xenon Pharmaceuticals Inc. | MORTIMER IAN | Pres, CEO, Dir | S - Sale | $45.01 | -97 | 31.2K | -0.3% | -$4,366 |
| DT | 2025-10-01 | 2025-10-01 | XENE | Xenon Pharmaceuticals Inc. | MORTIMER IAN | Pres, CEO, INTERIM CFO, Dir | S - Sale+OE | $40.16 | -25.0K | 31.3K | -44% | -$1.00M |
| DT | 2025-10-01 | 2025-10-01 | XENE | Xenon Pharmaceuticals Inc. | MORTIMER IAN | Pres, CEO, INTERIM CFO, Dir | M - OptEx | $7.69 | +25.0K | 56.3K | +80% | +$192.2K |
| DMT | 2025-01-27 | 2025-01-23+ | XENE | Xenon Pharmaceuticals Inc. | MORTIMER IAN | Pres, CEO, Dir | M - OptEx | $17.76 | +55.0K | 46.5K | New | +$976.8K |
| DMT | 2025-01-27 | 2025-01-23+ | XENE | Xenon Pharmaceuticals Inc. | MORTIMER IAN | Pres, CEO, Dir | S - Sale+OE | $40.25 | -55.0K | 31.3K | -64% | -$2.21M |
| DM | 2023-05-26 | 2023-05-24 | XENE | Xenon Pharmaceuticals Inc. | MORTIMER IAN | Pres, CEO, Dir | S - Sale+OE | $41.41 | -31.7K | 31.3K | -50% | -$1.31M |
| DM | 2023-05-26 | 2023-05-24 | XENE | Xenon Pharmaceuticals Inc. | MORTIMER IAN | Pres, CEO, Dir | M - OptEx | $9.60 | +69.3K | 48.6K | New | +$665.5K |
| DM | 2023-05-26 | 2023-05-24 | XENE | Xenon Pharmaceuticals Inc. | MORTIMER IAN | Pres, CEO, Dir | F - Tax | $41.84 | -12.4K | 40.9K | -23% | -$518.1K |
Purchase Sale Sale after option exercise All abbreviations